Streetbeat News

Revenues

CDIO

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) has launched HeartRisk, a data intelligence platform for employers to assess cardiovascular disease risks within their workforce. HeartRisk combines clinical data with industry and geographic data to provide actionable insights, aiming to reduce healthcare costs and improve productivity by mitigating cardiovascular disease impacts. The platform supports employers in making informed decisions on benefits and resource allocation. Cardio Diagnostics' Epi+Gen CHD and PrecisionCHD tests, which use AI and blood samples to assess heart attack risk and diagnose coronary heart disease, are part of the company's offerings to employers.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 1:43 pm

ISPR

Ispire Technology Inc. (NASDAQ:ISPR) has announced that its Malaysian subsidiary received three ISO certifications for its manufacturing facility, which is expected to increase gross margins by avoiding tariffs and improving production efficiency. The certifications are anticipated to enhance product quality, customer satisfaction, and access to global markets, contributing to the company's gross-margin expansion strategy.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 1:42 pm

RVPH

Reviva Pharmaceuticals Holdings, Inc. (RVPH) reported progress in its clinical program for brilaroxazine, a treatment for schizophrenia, with positive Phase 3 data and ongoing enrollment in a one-year OLE trial. The company expects to initiate a Phase 3 RECOVER-2 trial in Q1 2024 and release topline OLE trial data in Q4 2024. These developments are aimed at supporting an NDA submission to the FDA in 2025. Reviva also reported advancements in preclinical studies for brilaroxazine's potential in treating psoriasis and IPF, and raised $30 million in a registered direct offering.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 1:35 pm

OSIS

OSI Systems has received an order worth approximately $5 million to supply a U.S. hospital with patient monitoring solutions and related supplies. The order includes the Rothman Index, an AI-enabled predictive analytics tool, SafeNSound, a clinical workflow solution, and Xhibit Central Stations with XTR Telemetry and Qube bedside patient monitors.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 1:34 pm

AAGR

AAGRW

African Agriculture (AAGR) has announced an exclusive supply agreement to provide the full production from 700 hectares currently under development. This agreement is anticipated to contribute to the company's revenue in 2024 and 2025.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 1:31 pm

AAGR

African Agriculture Holdings Inc (NASDAQ:AAGR) has entered into a multi-year supply agreement with South Korea's Dr. Kahn to supply alfalfa. The deal involves the production from 700 hectares and is expected to contribute to African Agriculture's revenue in 2024 and 2025. The agreement is seen as a validation of African Agriculture's growth strategy and its role in global food security. AAGR's stock traded 5.98% lower at $1.10 in premarket trading.

Portfolio Pulse from Anusuya Lahiri

January 04, 2024 | 1:30 pm

SRRK

Scholar Rock, a biopharmaceutical company, has provided a corporate update for 2024, focusing on its antimyostatin pipeline for treating spinal muscular atrophy (SMA) and cardiometabolic disorders. The company has completed enrollment for its apitegromab Phase 3 SAPPHIRE trial in SMA patients, with topline data expected in Q4 2024. A Phase 2 trial for apitegromab in obesity is set to begin in mid-2024. Scholar Rock will also present new preclinical data on SRK-439, another myostatin inhibitor for obesity, at the Keystone Symposia in February. The company reports having approximately $280 million in cash and cash equivalents and will present at the 42nd Annual J.P. Morgan Healthcare Conference.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 1:30 pm

NKLA

Nikola Corporation reported the production of 42 Class 8 hydrogen fuel cell vehicles and the wholesale of 35 of these vehicles to customers in the US and Canada for the year 2023.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 1:19 pm

TSLA

Elon Musk, CEO of Tesla Inc. (NASDAQ:TSLA), discussed the potential of lithium batteries and solar energy to power industries sustainably, dismissing concerns about material shortages. He highlighted the rapid growth of battery production and the importance of energy buffering for electrical grids. The conversation follows the discovery of a large lithium reserve in California and Tesla's report on the Powerwall's performance.

Portfolio Pulse from Benzinga Neuro

January 04, 2024 | 1:14 pm

BLUE

Bluebird bio has entered into a second outcomes-based agreement for its gene therapy, LentiGlobin, for sickle cell disease, marketed as Zynteglo in the U.S. under the brand name LYFGENIA. This agreement expands coverage to approximately 200 million lives. The company will discuss the commercial launch details at the upcoming 42nd Annual J.P. Morgan Healthcare Conference, according to a recent SEC filing.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 1:09 pm